Skip to main content
Caplight Logo









Generare

Generare

Private
ParisHealthcare & Life Scienceshttps://generare.bio/

Last Round

Series A

Apr 2, 2026

Total Funding Raised

$28.4M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Generare is a biotechnology company that has developed a data-driven discovery platform to identify novel bioactive molecules from microbes for applications in medicine and other industries.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Application

Keywords

drug discoverysynthetic biologybioactive moleculesbiotech R&Dgenome mininglead optimizationcomputational biologybiosynthetic gene clustersbiotech platformdrug discovery platformin silico drug discoveryai drug discoverynatural product discoverybiotech partnershipdata as a service

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Generare Comparables

Compare Generare with similar companies based on industry and business-model similarity.

Generare comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hexagon Bio
82%
Empress Therapeutics
78%
Biomia
77%

Generare Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 2, 2026
SeedOct 8, 2024

Key People

Founding team and executive leadership

Guillaume Vandenesch

CEO Co-founder

Founding Team

Generare Investors

Notable investors and investment history

Generare investors
InvestorRounds
Saras CapitalSeed
AlvenSeries A
SynBioVenSeed
DaphniSeries A
Galion.exeSeries A, Seed
VIVES PartnersSeries A, Seed
Better AngleSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 467% MoM, from 381 to 2.2K.

  • Apr 2, 2026

    $23M round completed.

Generare Filings

Explore SEC and related filing metadata, where available.

Generare filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Generare's valuation, stock price, and market status.

Is Generare a public or private company?

Generare is a private company.

What is the current stock price of Generare?

Generare is a private company with no public stock price. No recent secondary market data is available.

How much is Generare worth (valuation)?

Valuation information for Generare is not publicly available.

Can I buy Generare stock?

Generare shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Generare's last funding round?

Generare's most recent funding round was Series A on April 2, 2026.

Who are the main investors in Generare?

Key investors in Generare include Alven, Daphni, Galion.exe, VIVES Partners, Teampact Ventures.

Will Generare IPO soon?

No public IPO plans have been announced for Generare.

How can I track Generare secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Generare's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range33
Year Founded2023
Last FundingApr 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?